Skip to main content

Quest Diagnostics Value Stock - Dividend - Research Selection

Quest diagnostics

ISIN: US74834L1008 , WKN: 904533

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Quest Diagnostics Incorporated provides diagnostic testing information and services in the United States and internationally. The company\'s Diagnostic Information Services business segment develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, gene-based and esoteric testing, anatomic pathology, and other diagnostic information services. This segment offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, Athena Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. Its Diagnostic Solutions segment offers risk assessment services for the life insurance industry; and health information technology solutions for healthcare organizations and clinicians. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Dividend Champion, Contender, And Challenger Highlights: Week Of March 29

2026-03-27
A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Access the full list here.

Quest Diagnostics Earnings Preview: What to Expect

2026-03-27
Quest Diagnostics is set to announce its first-quarter earnings next month, and Wall Street expects the company’s EPS to increase by a single digit.

3 Reasons to Avoid DGX and 1 Stock to Buy Instead

2026-03-23
Since September 2025, Quest has been in a holding pattern, posting a small return of 4.5% while floating around $195.43. However, the stock is beating the S&P 500’s flat performance during that period.

3 Mid-Cap Stocks with Warning Signs

2026-03-23
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract significant competition, spanning from industry behemoths with seemingly infinite resources to small, nimble players with chips on their shoulders.

Digi Power X to Announce 2025 Year End Financial Results on March 31st

2026-03-23
This news release constitutes a "designated news release" for the purposes of the Company's amended and restated prospectus supplement dated November 18, 2025, to its short form base shelf prospectus dated May 15, 2025. MIAMI, FL / ACCESS Newswire ...

How Guardant’s Shield Blood Test Rollout Through Quest Diagnostics (DGX) Has Changed Its Investment Story

2026-03-23
Earlier in March 2026, Guardant Health announced that its FDA-approved Shield blood-based colorectal cancer screening test is now widely available for physician order through Quest Diagnostics’ nationwide network, integrating into Quest accounts, electronic health records, and thousands of collection sites across the United States. This collaboration gives Shield access to roughly 650,000 Quest-connected clinician and hospital accounts, potentially reshaping how preventive colorectal cancer...

Quest Diagnostics to Release First Quarter Financial Results on April 21, 2026

2026-03-19
Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced today that it will report first quarter 2026 financial results on Tuesday, April 21, 2026, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day.

How Is Quest Diagnostics’ Stock Performance Compared to Other Healthcare Stocks?

2026-03-19
Quest Diagnostics has outpaced its healthcare peers over the past year, and analysts are maintaining a moderately positive outlook on its future performance.

Quest Diagnostics Inc. stock underperforms Wednesday when compared to competitors

2026-03-18
Quest Diagnostics Inc. stock underperforms Wednesday when compared to competitors

Zacks Industry Outlook Highlights Quest Diagnostics, DaVita, Option Care Health and Addus HomeCare

2026-03-18
DGX, DVA, OPCH and ADUS gain attention as telehealth, AI adoption and aging population drive growth in home healthcare services.